# U.S. Food and Drug Administration (FDA)

Type: regulator

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/us-food-and-drug-administration-fda-regulator
Canonical HTML page: https://gethealthbrief.com/entity/us-food-and-drug-administration-fda-regulator

## Timeline

- **2026-02-23**: Quicker Path Formalized — Official rollout of the streamlined regulatory framework for gene therapy approvals.
- **2025-06-15**: CBER Staffing Surge — FDA completes hiring of 100+ new reviewers dedicated to biologics and gene therapy.
- **2023-05-01**: START Pilot Program — FDA launches the Support for clinical Trials Advancing Rare disease Therapeutics pilot.
- **2017-12-19**: First Gene Therapy Approved — FDA approves Luxturna for a rare form of inherited vision loss.

## Recent coverage (5 stories)

### 42% Proteinuria Cut: FDA Backs Vera’s IgAN Drug with Accelerated Approval
2026-07-12 07:12:03 · Sentiment: Bullish · Impact: 8/10 · Sources: 2

The FDA’s accelerated approval of TRUTAKNA marks the first BAFF/APRIL inhibitor for IgA nephropathy, showing a 42% UPCR reduction over placebo. Healthcare providers now have a therapy targeting upstream disease drivers, with launch imminent and a confirmatory trial ongoing.
Full story: https://gethealthbrief.com/story/trutakna-accelerated-approval-iga-nephropathy-health

### Solius Pro Delivers UVB Therapy in 5 Minutes Weekly with 99% Less UV Risk
2026-06-18 01:32:45 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

Solius Labs launches the first OTC FDA-cleared personalized UVB light therapy device, claiming significant health benefits with minimal UV risk. For health consumers, it could offer a convenient way to boost vitamin D and improve mood without sun exposure.
Full story: https://gethealthbrief.com/story/solius-pro-uvb-therapy-5-minutes-99-less-risk

### FDA Launches Performance Bonuses to Accelerate Drug Review Timelines
2026-02-26 23:39:45 · Sentiment: Bullish · Impact: 7/10 · Sources: 5

The U.S. Food and Drug Administration is introducing a new incentive program that provides financial bonuses to staff members who complete drug application reviews ahead of schedule. This move aims to streamline the regulatory pipeline and reduce the backlog of pending therapies, though it raises questions regarding the balance between speed and clinical rigor.
Full story: https://gethealthbrief.com/story/fda-bonus-payments-speedy-drug-reviews

### FDA Accelerates Gene Therapy Approvals with New Regulatory Framework
2026-02-23 22:39:08 · Sentiment: Bullish · Impact: 8/10 · Sources: 8

The FDA has launched a streamlined regulatory pathway designed to expedite the development and review of gene therapies, particularly for rare diseases. This initiative marks a significant shift toward using surrogate endpoints and flexible trial designs to bring life-saving treatments to market faster.
Full story: https://gethealthbrief.com/story/fda-quicker-path-gene-therapies-regulation

### NG Biotech and Hardy Diagnostics Secure FDA Breakthrough for AMR Assays
2026-02-19 11:10:27 · Sentiment: Bullish · Impact: 7/10 · Sources: 2

NG Biotech and Hardy Diagnostics have received FDA Breakthrough Device Designation for two rapid diagnostic assays targeting multidrug-resistant pathogens. The NG-TEST Candida auris and NG-TEST Aci assays provide rapid, point-of-care identification of high-priority healthcare-associated infections.
Full story: https://gethealthbrief.com/story/ng-biotech-hardy-diagnostics-fda-breakthrough-amr

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.